Pcn74 Utilities Associated With Non-Small Cell Lung Cancer (Nsclc): A Community Study

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)

“…In contrast, docetaxel, and to a lesser extent pemetrexed, have more serious side effects including anemia and febrile neutropenia. These differences in side effects have quality of life implications as reflected by health state preference studies [13,14]. In addition, these side effects have cost implications with additional physician visits, hospitalizations, and therapies for side effects, including epogen and neupogen.…”

“…The utilities in our model were derived from a recent community based study from the UK, which used the EQ-5D and standard gamble interview to assess quality of life in advanced NSCLC (Table 3) [13]. The utility difference between IV and oral therapy was derived from a similar study, which used the EQ-5D and visual analog scale [3,14]. The disutility for adverse events was applied during the first month of therapy as the majority of AE's occur in the first month and would not be expected to last longer than 1 month.…”

A Review and Meta-Analysis of Utility Values for Lung Cancer

“…The final set consisted of 23 articles, with all articles presenting more than one utility, for a total of 223 unique utility values. [9][10][11][12][13][14][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51] Validity Assessment…”

Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial

“…Effects of treatment-related AEs on patient's quality of life were reported as disutilities, which factored in our analysis as one-time tariffs on the total QALYs (Table 1) stable disease without treatment from that for stable with oral or intravenous therapy. As an oral therapy, erlotinib is associated with smaller disutility compared to intravenous chemotherapy treatment [25]. The utility-weighted probabilities of being in individual simulation cycles added up to the patient's total QALYs over the time horizon.…”

“…See Table 2 Costs Proteomic test $3260 Drug acquisition Chemotherapy Erlotinib Docetaxel among all chemotherapy [29] 62.9% Cost [27] $3178 $6591 No. of cycles [29] 4.9 4.7 Administration and follow-up visits [30] Physician office visit $144 Infusion, 1 hour $133 Adverse events [13] See Table 2 Utilities Baseline utility (advanced NSCLC after 1st-line treatment) [24] 0.653 Treatment [25] Disutility upon chemotherapy −0.03 Disutility upon erlotinib −0.01 Adverse events [24] Disutility The cost of the proteomic test was $3260, based on the list price provided by the development company.…”